VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Carl C. Awh, MD, FASRS, of Tennessee Retina discusses the phase 3 Pagoda trial investigating the port delivery system with ranibizumab for diabetic macular edema.
“At 2 years, patients using the port delivery system refilled approximately every 6 months had similar visual and anatomic outcomes to patients receiving monthly injections of ranibizumab,” Awh said. “This was what we had hoped to see.”
These results reinforced Pagoda’s 1-year findings, in which the study met its primary endpoint of noninferiority of the PDS for visual outcomes compared with monthly ranibizumab injections, as Healio previously reported.
Collapse
Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts